文献速递肝病消化道肿瘤与早癌

甲胎蛋白、甲胎蛋白异质体及脱γ羧基凝血酶原作为肝细胞癌检测生物标志物的性能:美国一项三期生物标志物研究

The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-03

该研究为前瞻性标本收集、回顾性盲法评估(PRoBE)队列研究,纳入534例接受6个月影像学联合甲胎蛋白监测的肝硬化患者,其中50例发生肝细胞癌(68%为早期)。GALAD评分在各时间点对肝细胞癌的真阳性率最高,但假阳性率达21.5%至22.9%;在固定10%假阳性率下,GALAD与HES或单独AFP-L3相比无显著差异,曲线下面积在GALAD、HES、AFP-L3或DCP间亦无差异。

要点

  • GALAD真阳性率最高(全肝癌63.6%至73.8%,早期肝癌53.8%至63.3%),但假阳性率21.5%至22.9%。
  • 固定10%假阳性率下,GALAD真阳性率降至42.4%至46.9%,与HES或单独AFP-L3无显著差异。
  • GALAD、HES、AFP-L3或DCP的受试者工作特征曲线下面积间无差异,GALAD性能中等。

核心结论

  • GALAD与肝细胞癌检测灵敏度相当大的改善相关,但假阳性结果增加。
  • GALAD性能中等,与单独AFP-L3或HES无差异。

研究设计与样本

  • 前瞻性标本收集、回顾性盲法评估(PRoBE)队列研究,纳入接受每6个月影像学联合AFP监测的肝硬化患者。
  • 血液样本每6个月前瞻性收集,以回顾性盲法方式分析。
  • 分析在534例患者队列中进行,50例发生肝细胞癌(68%为早期),484例为影像学阴性对照。

主要发现

  • GALAD真阳性率:全肝癌在6、12、24个月内分别为63.6%、73.8%、71.4%;早期肝癌分别为53.8%、63.3%、61.8%。
  • GALAD假阳性率为21.5%至22.9%。
  • 固定10%假阳性率下,GALAD真阳性率降至42.4%、45.2%、46.9%,与HES(36.4%、40.5%、40.8%)或单独AFP-L3(39.4%、45.2%、44.9%)无差异。
  • GALAD、HES、AFP-L3或DCP的受试者工作特征曲线下面积间无差异。

关键数值与推荐

  • 基于已发表的生物标志物阈值计算任意或早期肝细胞癌的真阳性率和假阳性率,时间窗为诊断后6、12、24个月内。
  • 基于固定10%假阳性率下的最佳阈值估计真阳性率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: α-fetoprotein (AFP), AFP Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP) in combination or in GALAD (Gender, Age, AFP-L3, AFP, and DCP) were tested for hepatocellular carcinoma (HCC) surveillance in retrospective cohort and case-control studies. However, there is a paucity of prospective data and no phase III biomarker studies from North American populations. METHODS: We conducted a prospective specimen collection, retrospective blinded evaluation (PRoBE) cohort study in patients with cirrhosis enrolled in a 6-monthly surveillance with liver imaging and AFP. Blood samples were prospectively collected every 6 months and analyzed in a retrospective blinded fashion. True positive rate (TPR) and false positive rate (FPR) for any or early HCC were calculated within 6, 12, and 24 months of HCC diagnosis based on published thresholds for biomarkers individually, in combination and in GALAD and Hepatocellular Carcinoma Early Detection Screening (HES) scores. We calculated the area under the receiver operating curve and estimated TPR based on an optimal threshold at a fixed FPR of 10%. RESULTS: The analysis was conducted in a cohort of 534 patients; 50 developed HCC (68% early) and 484 controls with negative imaging. GALAD had the highest TPR (63.6%, 73.8%, and 71.4% for all HCC, and 53.8%, 63.3%, and 61.8 % for early HCC within 6, 12, and 24 months, respectively) but an FPR of 21.5% to 22.9%. However, there were no differences in the area under the receiver operating curve among GALAD, HES, AFP-L3, or DCP. At a fixed 10% FPR, TPR for GALAD dropped (42.4%, 45.2%, and 46.9%) and was not different from HES (36.4%, 40.5%, and 40.8%) or AFP-L3 alone (39.4%, 45.2%, and 44.9%). CONCLUSIONS: In a prospective cohort phase III biomarker study, GALAD was associated with a considerable improvement in sensitivity for HCC detection but an increase in false-positive results. GALAD performance was modest and not different from AFP-L3 alone or HES.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tayob N, Kanwal F, Alsarraj A, et al. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2022. PMID: 35124267. doi:10.1016/j.cgh.2022.01.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。